RTTR vs. KRON, GANX, NBRV, EGRX, OCUP, EYEN, NXTC, AADI, CLNN, and DARE
Should you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Kronos Bio (KRON), Gain Therapeutics (GANX), Nabriva Therapeutics (NBRV), Eagle Pharmaceuticals (EGRX), Ocuphire Pharma (OCUP), Eyenovia (EYEN), NextCure (NXTC), Aadi Bioscience (AADI), Clene (CLNN), and Daré Bioscience (DARE). These companies are all part of the "medical" sector.
Ritter Pharmaceuticals (NASDAQ:RTTR) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.
0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.1% of Kronos Bio shares are owned by institutional investors. 15.4% of Ritter Pharmaceuticals shares are owned by insiders. Comparatively, 23.4% of Kronos Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Ritter Pharmaceuticals has a beta of -0.43, indicating that its share price is 143% less volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.
Kronos Bio has a consensus target price of $4.13, suggesting a potential upside of 422.15%. Given Kronos Bio's higher probable upside, analysts plainly believe Kronos Bio is more favorable than Ritter Pharmaceuticals.
Ritter Pharmaceuticals received 284 more outperform votes than Kronos Bio when rated by MarketBeat users. Likewise, 70.23% of users gave Ritter Pharmaceuticals an outperform vote while only 66.67% of users gave Kronos Bio an outperform vote.
In the previous week, Kronos Bio had 1 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 1 mentions for Kronos Bio and 0 mentions for Ritter Pharmaceuticals. Kronos Bio's average media sentiment score of 1.89 beat Ritter Pharmaceuticals' score of 0.00 indicating that Kronos Bio is being referred to more favorably in the news media.
Ritter Pharmaceuticals has higher earnings, but lower revenue than Kronos Bio.
Ritter Pharmaceuticals has a net margin of 0.00% compared to Kronos Bio's net margin of -1,534.11%. Ritter Pharmaceuticals' return on equity of 0.00% beat Kronos Bio's return on equity.
Summary
Kronos Bio beats Ritter Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Ritter Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RTTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ritter Pharmaceuticals Competitors List
Related Companies and Tools
